News
New investments to support research and science across Canada Mar, 3, 2021
The Prime Minister, Justin Trudeau, today announced an investment to support more than 100 research projects and almost 1,000 researchers across the country.
According to the Announcement, this investment of more than C$518 million will ensure these researchers have the facilities and tools they need, and will fund projects that help us beat the pandemic and build a more resilient Canada.
The list of currently CFI FUNDED PROJECTS
Related Links
- Innovation Fund
- Canada Foundation for Innovation
- Ensuring Canadian researchers are well equipped to tackle the pandemic
- Prime Minister announces support for research staff in Canada
- Canada’s plan to mobilize science to fight COVID-19
Source:
Neuronix supplies world-class advanced electrophysiological instruments for clinical and experimental research at at affordable capital and operating costs.
Comprehensive databases and HL7-compatibility make the instruments ideal for the use in universities, research hospitals, and hospital networks.
Data export into statistical software makes the instruments ideal for advanced analysis and research.
World Health Organization: One in four people projected to have hearing problems by 2050 Mar, 2, 2021
The first-ever World Report on Hearing, released by the World Health Organization (WHO), projects that nearly 2.5 billion people worldwide ─ or 1 in 4 ─ will have some degree of hearing loss by 2050.
The Report, which is launched ahead of World Hearing Day on 3 March, underlines the need for efforts to prevent and address hearing loss by investing and expanding access to ear and hearing care services.
To contribute to such efforts, Neuronix offers the Neuro-Audio, one of the world’s best hearing assessment device that can be used in infants, children and adults.
In conjunction with the World Hearing Day, the special SALE prices – for any Neuro-Audio configuration – will be in effect for all orders received from the World Hearing Day March 3, 2021 for 3 months – until June 3, 2021.
For all online purchases, the SALE prices are reduced by 20%.
For all sales through a Purchase Order (PO) process, a pre-payment will be required, and a 20% discount will be applied in the Quotations. Please contact us for a Quotation request.
ABOUT NEURO-AUDIO
Neuro-Audio is one of the most comprehensive devices on the market that can record:
· Auditory Brainstem Response (ABR)
· Auditory Steady-State Response (ASSR)
· Electrocochleography (ECochG)
· P300
· Mismatch Negativity (MMN)
· Middle-latency Responses (MLR)
· Long-Latency responses (LLR)
· Distortion Product Otoacoustic Emissions (DPOAE)
· Transient Otoacoustic Emissions (TEOAE)
· Spontaneous Otoacoustic Emissions (SOAE)
· Pure-tone Screening Audiometry (PTA).
Clinical Evidence of COVID-19 Neurology and Importance of EEG Feb, 3, 2021
The recent clinical evidence shows that COVID-19 negatively affects the functioning of the central nervous system. Moreover, the degree of influence depends on the severity of the course of the disease. In critically ill patients, who have been in intensive care for a long time, even severe damage to the central nervous system is observed up to the appearance of non-convulsive epileptic seizures. The EEG method allows monitoring the state of the central nervous system of such patients and timely applying the necessary treatment methods in order to prevent severe consequences of the disease.
Here are some of the clinical papers, with corresponding citations, that describe the importance of the EEG method to diagnose patients with COVID-19:
Systematic review of EEG findings in 617 patients diagnosed with COVID-19
“EEG abnormalities are common in COVID-19 related encephalopathy and correlates with disease severity, preexisting neurological conditions including epilepsy and prolonged EEG monitoring. Frontal findings are frequent and have been proposed as a biomarker for COVID-19 encephalopathy.”
EEG findings in COVID-19 related encephalopathy
“In conclusion, our observations confirm the high sensitivity of the EEG and its localization value in encephalopathies, contributing to unravel also mild cases of COVID-19 related brain dysfunction. In detail, we have shown that COVID-19 related encephalopathy may be associated with a rather homogeneous EEG pattern consisting of a diffuse slowing of the background activity and loss of reactivity to external stimuli. Whether or not these EEG findings may be specific for COVID-19 related encephalopathy is unknown and deserves further investigation.”
COVID-19 associated encephalopathy: Is there a specific EEG pattern?
“We report the history of two patients with coronavirus infectious disease 2019 (COVID-19) whose electroencephalograms (EEG) found a unique pattern, never described up to now.”
Status epilepticus and other EEG findings in patients with COVID-19: A case series
“Status epilepticus was present in 2 out of our cohort of 5 critically ill patients who underwent EEG monitoring. These findings highlight the importance of EEG monitoring in high-risk patients with COVID-19 and encephalopathy. EEG recordings in such patients can identify pathological patterns that will benefit from treatment with anti-seizure medications.”
“Our study supports growing evidence that COVID‐19 can affect the central nervous system, although seizures are unlikely a common cause of encephalopathy. Seizures and epileptiform activity on EEG occurred infrequently, and having a history of epilepsy or seizure(s) prior to EEG testing was predictive of epileptiform findings. This has important implications for triaging EEG testing in this population.
The prevalence of epileptiform findings on electroencephalography (EEG) among patients critically ill due to COVID‐19 is 30%.”
The Emerging Spectrum of COVID-19 Neurology Jul, 19, 2020
In the recently published in the Brain article, The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings, the authors, Ross W Paterson and colleagues, presented preliminary clinical data indicating that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with neurological and neuropsychiatric illness.
The authors found that “SARS-CoV-2 infection is associated with a wide spectrum of neurological syndromes affecting the whole neuraxis, including the cerebral vasculature and, in some cases, responding to immunotherapies. The high incidence of acute disseminated encephalomyelitis, particularly with haemorrhagic change, is striking. This complication was not related to the severity of the respiratory COVID-19 disease.”